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PO Bo
k.kooimAbstract—Therapeutic ultrasound strategies that harness the mechanical activity of cavitation nuclei for benefi-
cial tissue bio-effects are actively under development. The mechanical oscillations of circulating microbubbles,
the most widely investigated cavitation nuclei, which may also encapsulate or shield a therapeutic agent in the
bloodstream, trigger and promote localized uptake. Oscillating microbubbles can create stresses either on nearby
tissue or in surrounding fluid to enhance drug penetration and efficacy in the brain, spinal cord, vasculature,
immune system, biofilm or tumors. This review summarizes recent investigations that have elucidated interac-
tions of ultrasound and cavitation nuclei with cells, the treatment of tumors, immunotherapy, the bloodbrain
and bloodspinal cord barriers, sonothrombolysis, cardiovascular drug delivery and sonobactericide. In particu-
lar, an overview of salient ultrasound features, drug delivery vehicles, therapeutic transport routes and pre-clini-
cal and clinical studies is provided. Successful implementation of ultrasound and cavitation nuclei-mediated drug
delivery has the potential to change the way drugs are administered systemically, resulting in more effective ther-
apeutics and less-invasive treatments. (E-mail: k.kooiman@erasmusmc.nl) © 2020 The Author(s). Published by
Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology. This is an open access article
under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key Words: Ultrasound, Cavitation nuclei, Therapy, Drug delivery, Bubblecell interaction, Sonoporation,
Sonothrombolysis, Bloodbrain barrier opening, Sonobactericide, Tumor.INTRODUCTION
Around the start of the European Symposium on Ultra-
sound Contrast Agents, ultrasound-responsive cavitation
nuclei were reported to have therapeutic potential.
Thrombolysis was reported to be accelerated in vitro
(Tachibana and Tachibana 1995), and cultured cellsddress correspondence to: Klazina Kooiman, Office Ee2302,
x 2040, 3000 CA Rotterdam, The Netherlands. E-mail:
an@erasmusmc.nl
1were transfected with plasmid DNA (Bao et al. 1997).
Since then, many research groups have investigated the
use of cavitation nuclei for multiple forms of therapy,
including tissue ablation and drug and gene delivery. In
the early years, the most widely investigated cavitation
nuclei were gas microbubbles, »110 mm in diameter
and coated with a stabilizing shell, whereas today both
solid and liquid nuclei, which can be as small as a few
hundred nanometers, are also being investigated. Drugs
can be co-administered with the cavitation nuclei or
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et al. 2014). The diseases that can be treated with ultra-
sound-responsive cavitation nuclei include but are not
limited to cardiovascular disease and cancer (Sutton
et al. 2013; Paefgen et al. 2015), the current leading
causes of death worldwide according to the World
Health Organization (Nowbar et al. 2019). This review
focuses on the latest insights into cavitation nuclei for
therapy and drug delivery from the physical and biologi-
cal mechanisms of bubblecell interaction to pre-clini-
cal (both in vitro and in vivo) and clinical (time span:
2014-2019) studies, with particular emphasis on the key
clinical applications. The applications covered in this
review are the treatment of tumors, immunotherapy,
bloodbrain barrier (BBB) and bloodspinal cord bar-
rier, dissolution of clots, cardiovascular drug delivery
and treatment of bacterial infections.CAVITATION NUCLEI FOR THERAPY
The most widely used cavitation nuclei are phos-
pholipid-coated microbubbles with a gas core. For the
128 pre-clinical studies included in the treatment sec-
tions of this review, the commercially available and clin-
ically approved Definity (Luminity in Europe;
octafluoropropane gas core, phospholipid coating) (Defi-
nity 2011; Nolsøe and Lorentzen 2016) microbubbles
were the most frequently used (in 22 studies). Definity
was used for studies on all applications discussed here,
mostly for opening the BBB (12 studies). SonoVue
(Lumason in the United States) is commercially avail-
able and clinically approved as well (sulfur hexafluoride
gas core, phospholipid coating) (Lumason 2016; Nolsøe
and Lorentzen 2016) and was used in a total of 14 studies
for treatment of non-brain tumors (e.g., Xing et al. 2016),
BBB opening (e.g., Goutal et al. 2018) and sonobacteri-
cide (e.g., Hu et al. 2018). Other commercially available
microbubbles were used that are not clinically approved,
such as BR38 (Schneider et al. 2011) in the study by
Wang et al. (2015d) and MicroMarker (VisualSonics) in
the study by Theek et al. (2016). Custom-made micro-
bubbles are as diverse as their applications, with special
characteristics tailored to enhance different therapeutic
strategies. Different types of gasses were used as the
core such as air (e.g., Eggen et al. 2014), nitrogen (e.g.,
Dixon et al. 2019), oxygen (e.g., Fix et al. 2018), octa-
fluoropropane (e.g., Pandit et al. 2019), perfluorobutane
(e.g., Dewitte et al. 2015), sulfur hexafluoride (Bae et al.
2016; Horsley et al. 2019) or a mixture
of gases such as nitric oxide and octafluoropropane
(Sutton et al. 2014) or sulfur hexafluoride and oxygen
(McEwan et al. 2015). While fluorinated gases improvethe stability of phospholipid-coated microbubbles (Rossi
et al. 2011), other gases can be loaded for therapeutic
applications, such as oxygen for treatment of tumors
(McEwan et al. 2015; Fix et al. 2018; Nesbitt et al. 2018)
and nitric oxide (Kim et al. 2014; Sutton et al. 2014) and
hydrogen gas (He et al. 2017) for treatment of cardiovas-
cular disease. The main phospholipid component of
custom-made microbubbles is usually a phosphatidyl-
choline such as 1,2-dipalmitoyl-sn-glycero-3-phospho-
choline (DPPC), used in 13 studies (e.g., Dewitte et al.
2015; Bae et al. 2016; Chen et al. 2016; Fu et al. 2019),
or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
used in 18 studies (e.g., Kilroy et al. 2014; Bioley et al.
2015; Dong et al. 2017; Goyal et al. 2017; Pandit et al.
2019). These phospholipids are popular because they are
also the main components in Definity (Definity 2011)
and SonoVue/Lumason (Lumason 2016), respectively.
Another key component of the microbubble coating is a
polyethylene glycol (PEG)ylated emulsifier such as pol-
yoxyethylene (40) stearate (PEG40-stearate; e.g., Kilroy
et al. 2014) or the most frequently used 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-carboxy(polyeth-
ylene glycol) (DSPEPEG2000; e.g., Belcik et al.
2017), which is added to inhibit coalescence and to
increase the in vivo half-life (Ferrara et al. 2009). In gen-
eral, two methods are used to produce custom-made
microbubbles: mechanical agitation (e.g., Ho et al. 2018)
and probe sonication (e.g., Belcik et al. 2015). Both
methods produce a population of microbubbles that is
polydisperse in size. Monodispersed microbubbles pro-
duced by microfluidics have recently been developed,
and are starting to gain attention for pre-clinical thera-
peutic studies. Dixon et al. (2019) used monodisperse
microbubbles to treat ischemic stroke.
Various therapeutic applications have inspired the
development of novel cavitation nuclei, which is dis-
cussed in depth in the companion review by Stride et al.
(2020). To improve drug delivery, therapeutics can be
either co-administered with or loaded onto the microbub-
bles. One strategy for loading is to create microbubbles
stabilized by drug-containing polymeric nanoparticles
around a gas core (Snipstad et al. 2017). Another strat-
egy is to attach therapeutic molecules or liposomes to
the outside of microbubbles, for example, by bio-
tinavidin coupling (Dewitte et al. 2015; McEwan et al.
2016; Nesbitt et al. 2018). Echogenic liposomes can be
loaded with different therapeutics or gases and have
been studied for vascular drug delivery (Sutton et al.
2014), treatment of tumors (Choi et al. 2014) and sono-
thrombolysis (Shekhar et al. 2017). Acoustic Cluster
Therapy (ACT) combines Sonazoid microbubbles with
droplets that can be loaded with therapeutics for
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ionic microbubbles utilized in the treatment sections of
this review were used mostly for vascular drug delivery,
with genetic material loaded on the microbubble surface
by charge coupling (e.g., Cao et al. 2015). Besides phos-
pholipids and nanoparticles, microbubbles can also be
coated with denatured proteins such as albumin. Optison
(Optison 2012) is a commercially available and clini-
cally approved ultrasound contrast agent that is coated
with human albumin and used in studies on treatment of
non-brain tumors (Xiao et al. 2019), BBB opening
(Kovacs et al. 2017b; Payne et al. 2017) and immuno-
therapy (Sta Maria et al. 2015). Nano-sized particles
cited in this review have been used as cavitation nuclei
for treatment of tumors, such as nanodroplets (e.g., Cao
et al. 2018) and nanocups (Myers et al. 2016); for BBB
opening (nanodroplets; Wu et al. 2018); and for sonobac-
tericide (nanodroplets; Guo et al. 2017a).
BUBBLECELL INTERACTION
Physics
The physics of the interaction between bubbles or
droplets and cells are described as these are the main
cavitation nuclei used for drug delivery and therapy.
Physics of microbubblecell interaction. Being
filled with gas and/or vapor makes bubbles highly
responsive to changes in pressure, and hence, exposure
to ultrasound can cause rapid and dramatic changes in
their volume. These volume changes in turn give rise to
an array of mechanical, thermal and chemical phenom-
ena that can significantly influence the bubbles’ immedi-
ate environment and mediate therapeutic effects. For the
sake of simplicity, these phenomena are discussed in the
context of a single bubble. It is important to note, how-
ever, that biological effects are typically produced by a
population of bubbles and the influence of inter-bubble
interactions should not be neglected.
Mechanical effects. A bubble in a liquid is subject to
multiple competing influences: the driving pressure of
the imposed ultrasound field; the hydrostatic pressure
imposed by the surrounding liquid; the pressure of the
gas and/or vapor inside the bubble; surface tension and
the influence of any coating material; the inertia of the
surrounding fluid; and damping caused by the viscosity
of the surrounding fluid and/or coating, thermal conduc-
tion and/or acoustic radiation.
The motion of the bubble is determined primarily
by the competition between the liquid inertia and the
internal gas pressure. This competition can be character-
ized by using the RayleighPlesset equation for bubble
dynamics to compare the relative contributions of theterms describing inertia and pressure to the acceleration
of the bubble wall (Flynn 1975a):
€R ¼ 3
2
_R
2
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þ pG Rð Þ þ p1 tð Þ
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rLR
 
¼ IFþ PF ð1Þ
where R is the time-dependent bubble radius with initial
value Ro, pG is the pressure of the gas inside the bubble,
p1 is the combined hydrostatic and time-varying pres-
sure in the liquid, s is the surface tension at the
gasliquid interface, rL is the liquid density, IF is inertia
factor and PF the pressure factor.
Flynn (1975a, 1975b) identified two scenarios: If
the PF is dominant when the bubble approaches its mini-
mum size, then the bubble will undergo sustained vol-
ume oscillations. If the inertia term is dominant (IF),
then the bubble will undergo inertial collapse, similar to
an empty cavity, after which it may rebound or it may
disintegrate. Which of these scenarios occurs is depen-
dent upon the bubble expansion ratio Rmax/Ro and,
hence, the bubble size and the amplitude and frequency
of the applied ultrasound field.
Both inertial and non-inertial bubble oscillations
can give rise to multiple phenomena that affect the
bubble’s immediate environment and hence are impor-
tant for therapy. These include:
1. Direct impingement: Even at moderate amplitudes of
oscillation, the acceleration of the bubble wall may be
sufficient to impose significant forces on nearby surfa-
ces, easily deforming fragile structures such as bio-
logical cell membranes (van Wamel et al. 2006; Kudo
2017) and blood vessel walls (Chen et al. 2011).
2. Ballistic motion: In addition to oscillating, the bubble
may undergo translation as a result of the pressure
gradient in the fluid generated by a propagating ultra-
sound wave (primary radiation force). Because of
their high compressibility, bubbles may travel at sig-
nificant velocities, sufficient to push them toward tar-
gets for improved local deposition of a drug (Dayton
et al. 1999) or to penetrate biological tissue (Caskey
et al. 2009; Bader et al. 2015; Acconcia et al. 2016).
3. Microstreaming: When a structure oscillates in a vis-
cous fluid there will be a transfer of momentum as a
result of interfacial friction. Any asymmetry in the
oscillation will result in a net motion of that fluid in
the immediate vicinity of the structure known as
microstreaming (Kolb and Nyborg 1956). This
motion will in turn impose shear stresses upon any
nearby surfaces, as well as increase convection within
the fluid. Because of the inherently non-linear nature
of bubble oscillations (eqn [1]), both non-inertial
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streaming, resulting in fluid velocities on the order of
1 mm/s (Pereno and Stride 2018). If the bubble is
close to a surface then it will also exhibit non-spheri-
cal oscillations, which increases the asymmetry and
hence the microstreaming even further (Nyborg 1958;
Marmottant and Hilgenfeldt 2003).
4. Microjetting: Another phenomenon associated with
non-spherical bubble oscillations near a surface is the
generation of a liquid jet during bubble collapse. If
there is sufficient asymmetry in the acceleration of
the fluid on either side of the collapsing bubble, then
the more rapidly moving fluid may deform the bubble
into a toroidal shape, causing a high-velocity jet to be
emitted on the opposite side. Microjetting has been
reported to be capable of producing pitting even in
highly resilient materials such as steel (Naude and
Ellis 1961; Benjamin and Ellis 1966). However, as
both the direction and velocity of the jet are deter-
mined by the elastic properties of the nearby surface,
its effects in biological tissue are more difficult to pre-
dict (Kudo and Kinoshita 2014). Nevertheless, as
reported by Chen et al. (2011), in many cases a bubble
will be sufficiently confined that microjetting will
have an impact on surrounding structures regardless
of jet direction.
5. Shock waves: An inertially collapsing cavity that
results in supersonic bubble wall velocities creates a
significant discontinuity in the pressure in the sur-
rounding liquid leading to the emission of a shock
wave, which may impose significant stresses on
nearby structures.
6. Secondary radiation force: At smaller amplitudes of
oscillation, a bubble will also generate a pressure
wave in the surrounding fluid. If the bubble is adja-
cent to a surface, interaction between this wave and
its reflection from the surface leads to a pressure gra-
dient in the liquid and a secondary radiation force on
the bubble. As with microjetting, the elastic properties
of the boundary will determine the phase difference
between the radiated and reflected waves and, hence,
whether the bubbles move toward or away from the
surface. Motion toward the surface may amplify the
effects of phenomena 1, 3 and 6.
Thermal effects. As described above, an oscillating
microbubble will re-radiate energy from the incident
ultrasound field in the form of a spherical pressure wave.
In addition, the non-linear character of the microbubble
oscillations will lead to the re-radiation of energy over a
range of frequencies. At moderate driving pressures, the
bubble spectrum will contain integer multiples (harmon-
ics) of the driving frequency; and at higher pressures,
also fractional components (sub- and ultraharmonics). Inbiological tissue, absorption of ultrasound increases with
frequency and this non-linear behavior thus also
increases the rate of heating (Hilgenfeldt et al. 2000;
Holt and Roy 2001). Bubbles will also dissipate energy
as a result of viscous friction in the liquid and thermal
conduction from the gas core, the temperature of which
increases during compression. Which mechanism is
dominant depends on the size of the bubble, the driving
conditions and the viscosity of the medium. Thermal
damping is, however, typically negligible in biomedical
applications of ultrasound as the time constant associated
with heat transfer is much longer than the period of the
microbubble oscillations (Prosperetti 1977).
Chemical effects. The temperature rise produced in the
surrounding tissue will be negligible compared with that
occurring inside the bubble, especially during inertial
collapse when it may reach several thousand Kelvin
(Flint and Suslick 1991). The gas pressure similarly
increases significantly. Although only sustained for a
very brief period, these extreme conditions can produce
highly reactive chemical species, in particular reactive
oxygen species (ROS), as well as the emission of electro-
magnetic radiation (sonoluminescence). ROS have been
reported to play a significant role in multiple biological
processes (Winterbourn 2008), and both ROS and sono-
luminescence may affect drug activity (Rosenthal et al.
2004; Trachootham et al. 2009; Beguin et al. 2019).
Physics of dropletcell interaction. Droplets con-
sist of an encapsulated quantity of a volatile liquid, such
as perfluorobutane (boiling point: 1.7˚C) or perfluoro-
pentane (boiling point: 29˚C), which is in a superheated
state at body temperature. Superheated state means that
although the volatile liquids have a boiling point below
37˚C, these droplets remain in the liquid phase and do
not exhibit spontaneous vaporization after injection.
Vaporization can be achieved instead by exposure to
ultrasound of significant amplitude via a process known
as acoustic droplet vaporization (ADV) (Kripfgans et al.
2000). Before vaporization, the droplets are typically
one order of magnitude smaller than the emerging bub-
bles, and the perfluorocarbon is inert and biocompatible
(Biro and Blais 1987). These properties enable a range
of therapeutic possibilities (Sheeran and Dayton 2012;
Lea-Banks et al. 2019). For example, unlike microbub-
bles, small droplets may extravasate from the leaky ves-
sels into tumor tissue because of the enhanced
permeability and retention (EPR) effect (Long et al.
1978; Lammers et al. 2012; Maeda 2012), and then be
turned into bubbles by ADV (Rapoport et al. 2009;
Kopechek et al. 2013). Loading the droplets with a drug
enables local delivery (Rapoport et al. 2009) by way of
ADV. The mechanism behind this is that the emerging
Fig. 1. Combined effect of non-linear propagation and focus-
ing of the harmonics in a perfluoropentane micrometer-sized
droplet. The emitted ultrasound wave has a frequency of
3.5 MHz and a focus at 3.81 cm, and the radius of the droplet is
10 mm for ease of observation. The pressures are given on the
axis of the droplet along the propagating direction of the ultra-
sound wave, and the shaded area indicates the location of the
droplet. Reprinted with permission from Sphak et al. (2014).
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streaming as described earlier in the Physics of the
MicrobubbleCell Interaction. It should be noted that
oxygen is taken up during bubble growth (Radhak-
rishnan et al. 2016), which could lead to hypoxia.
The physics of the dropletcell interaction is
largely governed by the ADV. In general, it has been
observed that ADV is promoted by the following factors:
large peak negative pressures (Kripfgans et al. 2000),
usually obtained by strong focusing of the generated
beam, high frequency of the emitted wave and a rela-
tively long distance between the transducer and the drop-
let. Another observation that has been made with
micrometer-sized droplets is that vaporization often
starts at a well-defined nucleation spot near the side of
the droplet where the acoustic wave impinges (Shpak
et al. 2014). These facts can be explained by considering
the two mechanisms that play a role in achieving a large
peak negative pressure inside the droplet: acoustic focus-
ing and non-linear ultrasound propagation (Shpak et al.
2016). In the following, lengths and sizes are related to
the wavelength, that is, the distance traveled by a wave
in one oscillation (e.g., a 1-MHz ultrasound wave that is
traveling in water with a wave speed, c, of 1500 m/s has
a wavelength, w (m), of c/f = 1500/106 = 0.0015, that is,
1.5 mm.
Acoustic focusing. Because the speed of sound in per-
fluorocarbon liquids is significantly lower than that in
water or tissue, refraction of the incident wave will occur
at the interface between these fluids, and the spherical
shape of the droplet will give rise to focusing. The
assessment of this focusing effect is not straightforward
because the traditional way of describing these phenom-
ena with rays that propagate along straight lines (the ray
approach) holds only for objects that are much larger
than the applied wavelength. In the current case, the fre-
quency of a typical ultrasound wave used for insonifica-
tion is in the order of 15 MHz, yielding wavelengths in
the order of 1500300 mm, while a droplet will be
smaller by two to four orders of magnitude. In addition,
using the ray approach, the lower speed of sound in per-
fluorocarbon would yield a focal spot near the backside
of the droplet, which is in contradiction to observations.
The correct way to treat the focusing effect is to solve
the full diffraction problem by decomposing the incident
wave, the wave reflected by the droplet and the wave
transmitted into the droplet into a series of spherical
waves. For each spherical wave, the spherical reflection
and transmission coefficients can be derived. Superposi-
tion of all the spherical waves yields the pressure inside
the droplet. Nevertheless, when this approach is only
applied to an incident wave with the frequency that is
emitted by the transducer, this will lead neither to theright nucleation spot nor to sufficient negative pressure
for vaporization. Nanoscale droplets may be too small to
make effective use of the focusing mechanism, and
ADV is therefore less dependent on the frequency.
Non-linear ultrasound propagation. High pressure
amplitudes, high frequencies and long propagation dis-
tances all promote non-linear propagation of an acoustic
wave (Hamilton and Blackstock 2008). In the time
domain, non-linear propagation manifests as an increas-
ing deformation of the shape of the ultrasound wave
with distance traveled. In the frequency domain, this
translates to increasing harmonic content, that is, fre-
quencies that are multiples of the driving frequency. The
total incident acoustic pressure p(t) at the position of a
nanodroplet can therefore be written as
p tð Þ ¼
X1
n ¼ 1
ancos nvt þ fnð Þ ð2Þ
where n is the number of a harmonic, an and fn are the
amplitude and phase of this harmonic and v is the angu-
lar frequency of the emitted wave. The wavelength of a
harmonic wave is a fraction of the emitted wavelength.
The aforementioned effects are both important in
the case of ADV and should therefore be combined. This
implies that first the amplitudes and phases of the inci-
dent non-linear ultrasound wave at the droplet location
should be computed. Next, for each harmonic, the dif-
fraction problem should be solved in terms of spherical
harmonics. Adding the diffracted waves inside the drop-
let with the proper amplitude and phase will then yield
the total pressure in the droplet. Figure 1 illustrates that
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fraction can cause a dramatic amplification of the peak
negative pressure in the micrometer-sized droplet, suffi-
cient for triggering droplet vaporization (Shpak et al.
2014). Moreover, the location of the negative pressure
peak also agrees with the observed nucleation spot.
After vaporization has started, the growth of the
emerging bubble is limited by inertia and heat transfer.
In the absence of the heat transfer limitation, the inertia
of the fluid that surrounds the bubble limits the rate of
bubble growth, which is linearly proportional to time
and inversely proportional to the square root of the den-
sity of the surrounding fluid. When inertia is neglected,
thermal diffusion is the limiting factor in the transport of
heat to drive the endothermic vaporization process of
perfluorocarbon, causing the radius of the bubble to
increase with the square root of time. In reality, both pro-
cesses occur simultaneously, where the inertia effect is
dominant at the early stage and the diffusion effect is
dominant at the later stage of bubble growth. The final
size that is reached by a bubble depends on the time that
a bubble can expand, that is, on the duration of the nega-
tive cycle of the insonifying pressure wave. It is there-
fore expected that lower insonification frequencies give
rise to larger maximum bubble size. Thus, irrespective
of their influence on triggering ADV, lower frequencies
would lead to more violent inertial cavitation effects and
cause more biological damage, as experimentally
observed for droplets with a radius in the order of
100 nm (Burgess and Porter 2019).
Biological mechanisms and bio-effects of ultrasound-
activated cavitation nuclei
The biological phenomena of sonoporation (i.e.,
membrane pore formation), stimulated endocytosis and
opening of cellcell contacts and the bio-effects of intra-
cellular calcium transients, ROS generation, cell mem-
brane potential change and cytoskeleton changes have
been observed for several years (Sutton et al. 2013;
Kooiman et al. 2014; Lentacker et al. 2014; Qin et al.
2018b). However, other bio-effects induced by ultra-
sound-activated cavitation nuclei have recently been dis-
covered. These include membrane blebbing as a
recovery mechanism for reversible sonoporation (both
for ultrasound-activated microbubbles [Leow et al.
2015] and upon ADV [Qin et al. 2018a]), extracellular
vesicle formation (Yuana et al. 2017), suppression of
efflux transporter P-glycoprotein (Cho et al. 2016; Aryal
et al. 2017) and BBB (bloodbrain barrier) transporter
genes (McMahon et al. 2018). At the same time, more
insight has been gained into the origin of the bio-effects,
largely through the use of live cell microscopy. For sono-
poration, real-time membrane pore opening and closure
dynamics were revealed with pores <30 mm2 closingwithin 1 min, while pores >100 mm2 did not reseal (Hu
et al. 2013) as well as immediate rupture of filamentary
actin at the pore location (Chen et al. 2014) and correla-
tion of intracellular ROS levels with the degree of sono-
poration (Jia et al. 2018). Real-time sonoporation and
opening of cellcell contacts in the same endothelial
cells have been reported as well for a single example
(Helfield et al. 2016). The applied acoustic pressure was
found to determine uptake of model drugs via sonopora-
tion or endocytosis in another study (De Cock et al.
2015). Electron microscopy revealed formation of tran-
sient membrane disruptions and permanent membrane
structures, that is, caveolar endocytic vesicles, upon
ultrasound and microbubble treatment (Zeghimi et al.
2015). A study by Fekri et al. (2016) revealed that
enhanced clathrin-mediated endocytosis and fluid-phase
endocytosis occur through distinct signaling mechanisms
upon ultrasound and microbubble treatment. The major-
ity of these bio-effects have been observed in in vitro
models using largely non-endothelial cells and may
therefore not be directly relevant to in vivo tissue, where
intravascular micron-sized cavitation nuclei will only
have contact with endothelial cells and circulating blood
cells. On the other hand, the mechanistic studies by Bel-
cik et al. (2015, 2017) and Yu et al. (2017) do reveal
translation from in vitro to in vivo. In these studies, ultra-
sound-activated microbubbles were found to induce a
shear-dependent increase in intravascular adenosine tri-
phosphate (ATP) from both endothelial cells and eryth-
rocytes, an increase in intramuscular nitric oxide and
downstream signaling through both nitric oxide and
prostaglandins, which resulted in augmentation of mus-
cle blood flow. Ultrasound settings were similar, namely,
1.3 MHz, mechanical index (MI) 1.3 for Belcik et al.
(2015, 2017) and 1 MHz, MI 1.5 for Yu et al. (2017),
with MI defined as MI = P/
ﬃﬃ
f
p
, where P_ is the derated
peak negative pressure of the ultrasound wave (in MPa)
and f the center frequency of the ultrasound wave (in
MHz).
Whether or not there is a direct relationship
between the type of microbubble oscillation and specific
bio-effects remains to be elucidated, although more
insight has been gained through ultrahigh-speed imaging
of the microbubble behavior in conjunction with live cell
microscopy. For example, there seems to be a microbub-
ble excursion threshold above which sonoporation
occurs (Helfield et al. 2016). Van Rooij et al. (2016) fur-
ther found that displacement of targeted microbubbles
enhanced reversible sonoporation and preserved cell via-
bility, whilst microbubbles that did not displace were
identified as the main contributors to cell death.
All of the aforementioned biological observations,
mechanisms and effects relate to eukaryotic cells. Study
of the biological effects of cavitation on, for example,
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ration can be achieved in Gram-negative bacteria, with
dextran uptake and gene transfection being reported in
Fusobacterium nucleatum (Han et al. 2007). More recent
studies have investigated the effect of microbubbles and
ultrasound on gene expression (Li et al. 2015; Dong
et al. 2017; Zhou et al. 2018). The findings are conflict-
ing because although they all reveal a reduction in
expression of genes involved in biofilm formation and
resistance to antibiotics, an increase in expression of
genes involved with dispersion and detachment of bio-
films was also found (Dong et al. 2017). This cavitation-
mediated bio-effect needs further investigation.
Modelling microbubblecelldrug interaction
Whilst there have been significant efforts to model
the dynamics of ultrasound-driven microbubbles (Faez
et al. 2013; Dollet et al. 2019), less attention has been
paid to the interactions between microbubbles and cells
or their impact upon drug transport. Currently there are
no models that describe the interactions between micro-
bubbles, cells and drug molecules. Several models have
been proposed for the microbubblecell interaction in
sonoporation focusing on different aspects: cell expan-
sion and microbubble jet velocity (Guo et al. 2017b), the
shear stress exerted on the cell membrane (Wu 2002;
Doinikov and Bouakaz 2010; Forbes and O’Brien 2012;
Yu and Chen 2014; Cowley and McGinty 2019), micro-
streaming (Yu and Chen 2014), the shear stress exerted
on the cell membrane in combination with microstream-
ing (Li et al. 2014) or other flow phenomena (Yu et al.
2015; Rowlatt and Lind 2017) generated by an oscillat-
ing microbubble. In contrast to the other models, Man
et al. (2019) propose that the microbubble-generated
shear stress does not induce pore formation, but is
instead due to microbubble fusion with the membrane
and subsequent “pull out” of cell membrane lipid mole-
cules by the oscillating microbubble. Models for pore
formation (e.g., Koshiyama and Wada 2011) and reseal-
ing (Zhang et al. 2019) in cell membranes have also
been developed, but these models neglect the mechanism
by which the pore is created. There is just one sonopora-
tion dynamics model, developed by Fan et al. (2012),
that relates the uptake of the model drug propidium
iodide (PI) to the size of the created membrane pore and
the pore resealing time for a single cell in an in vitro set-
ting. The model describes the intracellular fluorescence
intensity of PI as a function of time, F(t), by
F tð Þ ¼ a ¢pDC0 ¢ ro ¢ 1
b
1ebt  ð3Þ
where a is the coefficient that relates the amount of PI
molecules to the fluorescence intensity of PI-DNA and
PI-RNA, D is the diffusion coefficient of PI, C0 is theextracellular PI concentration, r0 is the initial radius of
the pore, b is the pore re-sealing coefficient and t is time.
The coefficient a is determined by the sensitivity of the
fluorescence imaging system, and if unknown, the equa-
tion can still be used because it is the pore size coeffi-
cient, a¢pDC0¢r0, that determines the initial slope of the
PI uptake pattern and is the scaling factor for the expo-
nential increase. A cell with a large pore will have a
steep initial slope of PI uptake, and the maximum PI
intensity quickly reaches the plateau value. A limitation
of this model is that eqn (3) is based on 2-D free diffu-
sion models, which holds for PI-RNA but not for PI-
DNA because the latter is confined to the nucleus. The
model is independent of cell type, as Fan et al. have
reported agreement with experimental results in both
kidney (Fan et al. 2012) and endothelial cells (Fan et al.
2013). Other researchers have also used this model for
endothelial cell studies and also classified the distribu-
tion of both the pore size and pore resealing coefficients
using principal component analysis (PCA) to determine
whether cells were reversibly or irreversibly sonopo-
rated. In the context of BBB opening, Hosseinkhah et al.
(2015) have modeled the microbubble-generated shear
and circumferential wall stress for 5-mm microvessels
upon microbubble oscillation at a fixed MI of 0.134 for a
range of frequencies (0.5, 1 and 1.5 MHz). The wall
stresses were dependent upon microbubble size (range
investigated: 218 mm in diameter) and ultrasound fre-
quency. Wiedemair et al. (2017) have also modelled the
wall shear stress generated by microbubble (2 mm in
diameter) destruction at 3 MHz for larger microvessels
(200 mm in diameter). The presence of red blood cells
was included in the model and was found to cause con-
finement of pressure and shear gradients to the vicinity
of the microbubble. Advances in methods for imaging
microbubblecell interactions will facilitate the devel-
opment of more sophisticated mechanistic models.TREATMENT OF TUMORS (NON-BRAIN)
The structure of tumor tissue varies significantly
from that of healthy tissue which has important implica-
tions for its treatment. To support the continuous expan-
sion of neoplastic cells, the formation of new vessels
(i.e., angiogenesis) is needed (Junttila and de Sauvage
2013). As such, a rapidly developed, poorly organized
vasculature with enlarged vascular openings arises.
Between these vessels, large avascular regions exist,
which are characterized by a dense extracellular matrix,
high interstitial pressure, low pH and hypoxia. More-
over, a local immunosuppressive environment is formed,
preventing possible anti-tumor activity by the immune
system.
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pathophysiology of tumors, treatment remains challeng-
ing. Chemotherapeutic drugs are typically administered
to abolish the rapidly dividing cancer cells. Yet, their
cytotoxic effects are not limited to cancer cells, causing
dose-limiting off-target effects. To overcome this hurdle,
chemotherapeutics are often encapsulated in nano-sized
carriers, that is, nanoparticles, that are designed to spe-
cifically diffuse through the large openings of tumor vas-
culature, while being excluded from healthy tissue by
normal blood vessels (Lammers et al. 2012; Maeda
2012). Despite being highly promising in pre-clinical
studies, drug-containing nanoparticles have exhibited
limited clinical success because of the vast heterogeneity
in tumor vasculature (Barenholz 2012; Lammers et al.
2012; Wang et al. 2015d). In addition, drug penetration
into the deeper layers of the tumor can be constrained by
high interstitial pressure and a dense extracellular matrix
in the tumor. Furthermore, acidic and hypoxic regions
limit the efficacy of radiation- and chemotherapy-based
treatments because of biochemical effects (Mehta et al.
2012; McEwan et al. 2015; Fix et al. 2018). Ultrasound-
triggered microbubbles are able to alter the tumor
environment locally, thereby improving drug deliveryFig. 2. Ultrasound-activated microbubbles can locally alter t
enhanced permeability, improved contact, reduced hypoxiato tumors. These alterations are schematically repre-
sented in Figure 2 and include improving vascular
permeability, modifying the tumor perfusion, reducing
local hypoxia and overcoming the high interstitial
pressure.
Several studies have found that ultrasound-driven
microbubbles improved delivery of chemotherapeutic
agents in tumors, which resulted in increased anti-tumor
effects (Wang et al. 2015d; Snipstad et al. 2017; Zhang
et al. 2018). Moreover, several gene products could be
effectively delivered to tumor cells via ultrasound-driven
microbubbles, resulting in a downregulation of tumor-
specific pathways and an inhibition in tumor growth
(Kopechek et al. 2015; Zhou et al. 2015). Theek et al.
(2016) furthermore confirmed that nanoparticle accumu-
lation can be achieved in tumors with low EPR effect.
Drug transport and distribution through the dense tumor
matrix and into regions with elevated interstitial pressure
are often the limiting factors in peripheral tumors. As a
result, several reports have indicated that drug penetra-
tion into the tumor remained limited after sonoporation,
which may impede the eradication of the entire tumor
tissue (Eggen et al. 2014; Wang et al. 2015d; Wei et al.
2019). Alternatively, microbubble cavitation can affecthe tumor microenvironment through four mechanisms:
and altered perfusion. ROS = reactive oxygen species.
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vascular shutdown have been reported ex vivo (Keravnou
et al. 2016) and in vivo (Hu et al. 2012; Goertz 2015;
Yemane et al. 2018). These effects were seen at higher
ultrasound intensities (>1.5 MPa) and are believed to
result from inertial cavitation leading to violent micro-
bubble collapses. As blood supply is needed to maintain
tumor growth, vascular disruption might form a different
approach to cease tumor development. Microbubble-
induced microvascular damage was able to complement
the direct effects of chemotherapeutics and antivascular
drugs by secondary ischemia-mediated cytotoxicity,
which led to tumor growth inhibition (Wang et al.
2015a; Ho et al. 2018; Yang et al. 2019b). In addition, a
synergistic effect between radiation therapy and ultra-
sound-stimulated microbubble treatment was observed,
as radiation therapy also induces secondary cell death by
endothelial apoptosis and vascular damage (Lai et al.
2016; Daecher et al. 2017). Nevertheless, several adverse
effects have been reported because of excessive vascular
disruption, including hemorrhage, tissue necrosis and the
formation of thrombi (Goertz 2015; Wang et al. 2015d;
Snipstad et al. 2017).
Furthermore, oxygen-containing microbubbles can
provide a local oxygen supply to hypoxic areas, render-
ing oxygen-dependent treatments more effective. This is
of interest for sonodynamic therapy, which is based on
the production of cytotoxic ROS by a sonosensitizing
agent upon activation by ultrasound in the presence of
oxygen (McEwan et al. 2015, 2016; Nesbitt et al. 2018).
As ultrasound can be used to stimulate the release of
oxygen from oxygen-carrying microbubbles while
simultaneously activating a sonosensitizer, this approach
has been reported to be particularly useful for the treat-
ment of hypoxic tumor types (McEwan et al. 2015; Nes-
bitt et al. 2018). Additionally, low oxygenation promotes
resistance to radiotherapy, which can be circumvented
by a momentary supply of oxygen. Based on this notion,
oxygen-carrying microbubbles were used to improve the
outcome of radiotherapy in a rat fibrosarcoma model
(Fix et al. 2018).
Finally, ultrasound-activated microbubbles promote
convection and induce acoustic radiation forces. As
such, closer contact with the tumor endothelium and an
extended contact time can be obtained (Kilroy et al.
2014). Furthermore, these forces may counteract the ele-
vated interstitial pressure present in tumors (Eggen et al.
2014; Lea-Banks et al. 2016; Xiao et al. 2019).
Apart from their ability to improve tumor uptake,
microbubbles can be used as ultrasound-responsive drug
carriers to reduce the off-target effects of chemothera-
peutics. By loading the drugs or drug-containing nano-
particles directly into or onto the microbubbles, a spatial
and temporal control of drug release can be obtained,thereby reducing exposure to other parts of the body
(Yan et al. 2013; Snipstad et al. 2017). Moreover, several
studies have reported improved anti-cancer effects from
treatment with drug-coupled microbubbles, compared
with a co-administration approach (Burke et al. 2014;
Snipstad et al. 2017). Additionally, tumor neovasculature
expresses specific surface receptors that can be targeted
by specific ligands. Adding such targeting moieties to
the surface of (drug-loaded) microbubbles improves site-
targeted delivery and has been found to potentiate this
effect further (Bae et al. 2016; Xing et al. 2016; Luo
et al. 2017).
Phase-shifting droplets and gas-stabilizing solid
agents (e.g., nanocups) have the unique ability to benefit
from both EPR-mediated accumulation in the “leaky”
parts of the tumor vasculature because of their small
sizes, as well as from ultrasound-induced permeabiliza-
tion of the tissue structure (Zhou 2015; Myers et al.
2016; Liu et al. 2018b; Zhang et al. 2018). Several
research groups have reported tumor regression after
treatment with acoustically active droplets (Gupta et al.
2015; van Wamel et al. 2016; Cao et al. 2018; Liu et al.
2018b) or gas-stabilizing solid particles (Min et al. 2016;
Myers et al. 2016). A different approach to the use of
droplets for tumor treatment is ACT, which is based on
microbubble-droplet clusters that upon ultrasound expo-
sure, undergo a phase shift to create large bubbles that
can transiently block capillaries (Sontum et al. 2015).
Although the mechanism behind the technique is not yet
fully understood, studies have reported improved deliv-
ery and efficacy of paclitaxel and Abraxane in xenograft
prostate tumor models (van Wamel et al. 2016; Kotopou-
lis et al. 2017). Another use of droplets for tumor treat-
ment is enhanced high-intensity focused ultrasound
(HIFU)-mediated heating of tumors (Kopechek et al.
2014).
Although microbubble-based drug delivery to solid
tumors shows great promise, it also faces important chal-
lenges. The ultrasound parameters used in in vivo studies
highly vary between research groups, and no consensus
was found on the oscillation regime that is believed to be
responsible for the observed effects (Wang et al. 2015d;
Snipstad et al. 2017). Moreover, longer ultrasound pulses
and increased exposure times are usually applied in com-
parison to in vitro reports (Roovers et al. 2019c). This
could promote additional effects such as microbubble
clustering and microbubble translation, which could
cause local damage to the surrounding tissue as well
(Roovers et al. 2019a). To elucidate these effects further,
fundamental in vitro research remains important. There-
fore, novel in vitro models that more accurately mimic
the complexity of the in vivo tumor environment are cur-
rently being explored. Park et al. (2016) engineered a
perfusable vessel-on-a-chip system and reported
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lining this microvascular network. While such microflui-
dic chips could be extremely useful to study the interac-
tions of microbubbles with the endothelial cell barrier,
special care of the material of the chambers should be
taken to avoid ultrasound reflections and standing waves
(Beekers et al. 2018). Alternatively, 3-D tumor spheroids
have been used to study the effects of ultrasound and
microbubble-assisted drug delivery on penetration and
therapeutic effect in a multicellular tumor model
(Roovers et al. 2019b). Apart from expanding the knowl-
edge on microbubbletissue interactions in detailed
parametric studies in vitro, it will be crucial to obtain
improved control over the microbubble behavior in vivo,
and link this to the therapeutic effects. To this end,
passive cavitation detection to monitor microbubble cav-
itation behavior in real time is currently under develop-
ment, and could provide better insights in the future
(Choi et al. 2014; Graham et al. 2014; Haworth et al.
2017). Efforts are being committed to construction of
custom-built delivery systems, which can be equipped
with multiple transducers allowing drug delivery guided
by ultrasound imaging and/or passive cavitation detec-
tion (Escoffre et al. 2013; Choi et al. 2014; Wang et al.
2015c; Paris et al. 2018).Clinical studies
Pancreatic cancer. The tolerability and therapeu-
tic potential of improved chemotherapeutic drug delivery
using microbubbles and ultrasound were first investi-
gated for the treatment of inoperable pancreatic ductal
adenocarcinoma at Haukeland University Hospital, Nor-
way (Kotopoulis et al. 2013; Dimcevski et al. 2016). In
this clinical trial, gemcitabine was administered by intra-
venous injection over 30 min. During the last 10 min of
chemotherapy, an abdominal echography was performed
to locate the position of pancreatic tumor. At the end of
chemotherapy, 0.5 mL of SonoVue microbubbles fol-
lowed by 5 mL saline was intravenously injected every
3.5 min to ensure their presence throughout the whole
sonoporation treatment. Pancreatic tumors were exposed
to ultrasound (1.9 MHz, MI 0.2, 1% DC) using a 4C cur-
vilinear probe (GE Healthcare) connected to an LOGIQ
9 clinical ultrasound scanner. The cumulative ultrasound
exposure was only 18.9 s. All clinical data indicated that
microbubble-mediated gemcitabine delivery did not
induce any serious adverse events in comparison to che-
motherapy alone. At the same time, tumor size and
development were characterized according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria. In addition, Eastern Cooperative Oncology
Group performance status was used to monitor the thera-
peutic efficacy of microbubble-mediated gemcitabinedelivery. All 10 patients tolerated an increased number
of gemcitabine cycles compared with treatment with
chemotherapy alone from historical controls (8.3 § 6 vs.
13.8 § 5.6 cycles, p < 0.008), thus reflecting an
improved physical state. After 12 treatment cycles, one
patient’s tumor exhibited a twofold decrease in tumor
size. This patient was excluded from this clinical trial to
be treated with radiotherapy and then with pancreatec-
tomy. In 5 of the 10 patients, the maximum tumor diame-
ter was partially decreased from the first to last
therapeutic treatment. Subsequently, a consolidative
radiotherapy or a FOLFIRINOX treatment, a bolus and
infusion of 5-fluorouracil, leucovorin, irinotecan and
oxaliplatin, was offered to them. The median survival
was significantly increased from 8.9 to 17.6 mo
(p = 0.0001). Together, these results indicate that drug
delivery using clinically approved microbubbles, chemo-
therapeutics and ultrasound is feasible and compatible
with respect to clinical procedures. Nevertheless, the
authors did not provide any evidence that the improved
therapeutic efficacy of gemcitabine was related to an
increase in intra-tumoral bioavailability of the drug. In
addition, the effects of microbubble-assisted ultrasound
treatment alone on tumor growth were not investigated,
while recent publications describe that according to the
ultrasound parameters, such treatment could induce a
significant decrease in tumor volume through a reduction
in tumor perfusion as described above.
Hepatic metastases from the digestive system. A
tolerability study of chemotherapeutic delivery using
microbubble-assisted ultrasound for the treatment of
liver metastases from gastrointestinal tumors and pancre-
atic carcinoma was conducted at Beijing Cancer Hospi-
tal, China (Wang et al. 2018). Thirty minutes after
intravenous infusion of chemotherapy (for both mono-
therapy and combination therapy), 1 mL of SonoVue
microbubbles was intravenously administered and was
repeated another five times in 20 min. An ultrasound
probe (C1-5 abdominal convex probe; GE Healthcare,
USA) was positioned on the tumor lesion, which was
exposed to ultrasound at different MIs (0.41) in con-
trast mode using a LogiQ E9 scanner (GE Healthcare,
USA). The primary aims of this clinical trial were to
evaluate the tolerability of this therapeutic procedure
and to explore the largest MI and ultrasound treatment
time that cancer patients can tolerate. According to the
clinical tolerability evaluation, all 12 patients exhibited
no serious adverse events. The authors reported that the
microbubble-mediated chemotherapy led to fever in 2
patients. However, there is no clear evidence this is
related to the microbubble and ultrasound treatment.
Indeed, in the absence of direct comparison of these
results with a historical group of patients receiving the
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link between the fever and the chemotherapy alone. All
adverse side effects were resolved with symptomatic
medication. In addition, the severity of side effects did
not worsen with increases in MI, suggesting that micro-
bubble-mediated chemotherapy is a tolerable procedure.
The secondary aims were to assess the efficacy of this
therapeutic protocol using contrast-enhanced computed
tomography (CT) and magnetic resonance imaging
(MRI). Thus, tumor size and development were charac-
terized according to the RECIST criteria. Half of the
patients had stable disease, and one patient obtained a
partial response after the first treatment cycle. The
median progression-free survival was 91 d. However,
comparison and interpretation of results are very difficult
because none of the patients were treated with the same
chemotherapeutics, MI and/or number of treatment
cycles. The results of tolerability and efficacy evalua-
tions should be compared with those for patients receiv-
ing the chemotherapy on its own to clearly identify the
therapeutic benefit of combining therapy with ultra-
sound-driven microbubbles. Similar to the pancreatic
clinical study, no direct evidence of enhanced therapeu-
tic bioavailability of the chemotherapeutic drug after the
treatment was provided. This investigation is all the
more important as the ultrasound and microbubble treat-
ment was applied 30 min after intravenous chemother-
apy (for both monotherapy and combination therapy)
independently of drug pharmacokinetics and metabo-
lism.
Ongoing and upcoming clinical trials. Currently,
two clinical trials are ongoing: (i) Professor F. Kiessling
(RWTH Aachen University, Germany) proposes examin-
ing whether the exposure of early primary breast cancer
to microbubble-assisted ultrasound during neoadjuvant
chemotherapy results in increased tumor regression in
comparison to that after ultrasound treatment alone
(NCT03385200). (ii) Dr. J. Eisenbrey (Sidney Kimmel
Cancer Center, Thomas Jefferson University, USA) is
investigating the therapeutic potential of perflutren protein
type A microspheres in combination with microbubble-
assisted ultrasound in radioembolization therapy of liver
cancer (NCT03199274).
A proof of concept study (NCT03458975) has been
set in Tours Hospital, France, for treating non-resectable
liver metastases. The aim of this trial is to perform a fea-
sibility study with the development of a dedicated ultra-
sound imaging and delivery probe with a therapy
protocol optimized for patients with hepatic metastases
of colorectal cancer and who are eligible for monoclonal
antibodies in combination with chemotherapy. A dedi-
cated 1.5-D ultrasound probe has been developed and
interconnected to a modified Aixplorer imaging platform(Supersonic Imagine, Aix-en-Provence, France). The
primary objective of the study is to determine the rate of
objective response at 2 mo for lesions receiving opti-
mized and targeted delivery of systemic chemotherapy
combining bevacizumab and FOLFIRI compared with
those treated with only the systemic chemotherapy regi-
men. The secondary objective is to determine the tolera-
bility of this local approach of optimized intra-tumoral
drug delivery during the 3 mo of follow-up, by assessing
tumor necrosis, tumor vascularity and pharmacokinetics
of bevacizumab and by profiling cytokine expression
spatially.IMMUNOTHERAPY
Cancer immunotherapy is considered to be one of
the most promising strategies to eradicate cancer as it
makes use of the patient’s own immune system to selec-
tively attack and destroy tumor cells. It is a common
name that refers to a variety of strategies that aim to
unleash the power of the immune system by either boost-
ing antitumoral immune responses or flagging tumor
cells to make them more visible to the immune system.
The principle is that tumors express specific tumor anti-
gens which are not expressed or expressed to a much
lesser extent by normal somatic cells and hence can be
used to initiate a cancer-specific immune response. In
this section we aim to give insight into how microbub-
bles and ultrasound have been applied as useful tools to
initiate or sustain different types of cancer immunother-
apy, as illustrated in Figure 3.
When Ralph Steinman (Steinman et al. 1979) dis-
covered the dendritic cell (DC) in 1973, its central role
in the initiation of immunity made it an attractive target
to evoke specific antitumoral immune responses. Indeed,
these cells very efficiently capture antigens and present
them to T lymphocytes in major histocompatibility com-
plexes (MHCs), thereby bridging the innate and adaptive
immune systems. More specifically, exogenous antigens
engulfed via the endolysosomal pathway are largely pre-
sented to CD4+ T cells via MHC-II, whereas endoge-
nous, cytoplasmic proteins are shuttled to MHC-I
molecules for presentation to CD8+ cells. As such, either
CD4+ helper T cells or CD8+ cytotoxic T-cell responses
are induced. The understanding of this pivotal role
played by DCs formed the basis for DC-based vaccina-
tion, where a patient’s DCs are isolated, modified ex vivo
to present tumor antigens and re-administered as a cellu-
lar vaccine. DC-based therapeutics, however, suffer
from a number of challenges, of which the expensive
and lengthy ex vivo procedure for antigen loading and
activation of DCs is the most prominent (Santos and But-
terfield 2018). In this regard, microbubbles have been
investigated for direct delivery of tumor antigens to
Fig. 3. Schematic overview of how microbubbles (MB) and ultrasound (US) have been found to contribute to cancer
immunotherapy. From left to right: Microbubbles can be used as antigen carriers to stimulate antigen uptake by dendritic
cells. Microbubbles and ultrasound can alter the permeability of tumors, thereby increasing the intra-tumoral penetration
of adoptively transferred immune cells or checkpoint inhibitors. Finally, exposing tissues to cavitating microbubbles can
induce sterile inflammation by the local release of damage-associated molecular patterns (DAMPS).
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intact microbubbles are rapidly phagocytosed by both
murine and human DCs, resulting in rapid and efficient
uptake of surface-coupled antigens without the use of
ultrasound. Subcutaneous injection of microbubbles
loaded with the model antigen ovalbumin (OVA)
resulted in the activation of both CD8+ and CD4+ T cells.
Effectively, these T-cell responses could partially protect
vaccinated mice against an OVA-expressing Listeria
infection. Dewitte et al. (2014) investigated a different
approach, making use of messenger RNA (mRNA)-
loaded microbubbles combined with ultrasound to trans-
fect DCs. As such, they were able to deliver mRNA
encoding both tumor antigens and immunomodulating
molecules directly to the cytoplasm of the DCs. As a
result, preferential presentation of antigen fragments in
MHC-I complexes was ensured, favoring the induction
of CD8+ cytotoxic T cells. In a therapeutic vaccination
study in mice bearing OVA-expressing tumors, injection
of mRNA-sonoporated DCs caused a pronounced slow-
down of tumor growth and induced complete tumor
regression in 30% of the vaccinated animals. Interest-
ingly, in humans, intradermally injected microbubbles
have been used as sentinel lymph node detectors as they
can easily drain from peripheral sites to the afferentlymph nodes (Sever et al. 2012a, 2012b). As lymph
nodes are the primary sites of immune induction, the
interaction of microbubbles with intranodal DCs, could
be of high value. To this end, Dewitte et al. (2015) found
that mRNA-loaded microbubbles were able to rapidly
and efficiently migrate to the afferent lymph nodes after
intradermal injection in healthy dogs. Unfortunately, fur-
ther translation of this concept to an in vivo setting is not
straightforward, as it prompts the use of less accessible
large animal models (e.g., pigs, dogs). Indeed, con-
versely to what has been reported in humans, lymphatic
drainage of subcutaneously injected microbubbles is
very limited in the small animal models typically used in
pre-clinical research (mice and rats), which is the result
of substantial differences in lymphatic physiology.
Another strategy in cancer immunotherapy is adop-
tive cell therapy, in which ex vivo manipulated immune
effector cells, mainly T cells and natural killer (NK)
cells, are employed to generate a robust and selective
anticancer immune response (Yee 2018; Hu et al. 2019).
These strategies have mainly led to successes in hemato-
logical malignancies, not only because of the availability
of selective target antigens, but also because of the
accessibility of the malignant cells (Khalil et al. 2016;
Yee 2018). By contrast, in solid tumors, and especially
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or NK cells to the tumor proved to be one of the main
reasons for the low success rates, making the degree of
tumor infiltration an important factor in disease progno-
sis (Childs and Carlsten 2015; Gras Navarro et al. 2015;
Yee 2018). To address this, focused ultrasound and
microbubbles have been used to make tumors more
accessible to cellular therapies. The first demonstration
of this concept was provided by Alkins et al. (2013),
who used a xenograft HER-2-expressing breast cancer
brain metastasis model to determine whether ultrasound
and microbubbles could allow intravenously infused NK
cells to cross the BBB. By loading the NK cells with
superparamagnetic iron oxide nanoparticles, the accu-
mulation of NK cells in the brain could be tracked and
quantified via MRI. An enhanced accumulation of NK
cells was found when the cells were injected immedi-
ately before BBB disruption. Importantly NK cells
retained their activity and ultrasound treatment resulted
in a sufficient NK-to-tumor cell ratio to allow effective
tumor cell killing (Alkins et al. 2016). In contrast, very
few NK cells reached the tumor site when BBB disrup-
tion was absent or performed before NK cell infusion.
Although it is not known for certain why timing had
such a significant impact on NK extravasation, it is likely
that the most effective transfer to the tissue occurs at the
time of insonification, and that the barrier is most open
during this time (Marty et al. 2012). Possible other
explanations include the difference in size of the tempo-
ral BBB openings or a possible alternation in the expres-
sion of specific leukocyte adhesion molecules by the
BBB disruption, thus facilitating the translocation of NK
cells. Also, for tumors where BBB crossing is not an
issue, ultrasound has been used to improve delivery of
cellular therapeutics. Sta Maria et al. (2015) reported
enhanced tumor infiltration of adoptively transferred NK
cells after treatment with microbubbles and low-dose
focused ultrasound. This result was confirmed by Yang
et al. (2019a) in a more recent publication where the
homing of NK cells more than doubled after microbub-
ble injection and ultrasound treatment of an ovarian
tumor. Despite the enhanced accumulation, however, the
authors did not observe an improved therapeutic effect,
which might be owing to the limited number of treat-
ments that were applied or the immunosuppressive
tumor microenvironment that counteracts the cytotoxic
action of the NK cells.
There is growing interest in exploring the effect of
microbubbles and ultrasound on the tumor microenvi-
ronment, as recent work has indicated that BBB disrup-
tion with microbubbles and ultrasound may induce
sterile inflammation. Although a strong inflammatory
response may be detrimental in the case of drug delivery
across the BBB, it might be interesting to further studythis inflammatory response in solid tumors as it might
induce the release of damage-associated molecular pat-
terns (DAMPS) such as heat-shock proteins and inflam-
matory cytokines. This could shift the balance toward a
more inflammatory microenvironment that could pro-
mote immunotherapeutic approaches. As reported by
Liu et al. (2012) exposure of a CT26 colon carcinoma
xenograft to microbubbles and low-pressure pulsed ultra-
sound increased cytokine release and triggered lympho-
cyte infiltration. Similar data have been reported by
Hunt et al. (2015). In their study, ultrasound treatment
caused a complete shutdown of tumor vasculature fol-
lowed by the expression of hypoxia-inducible factor 1a
(HIF-1a), a marker of tumor ischemia and tumor necro-
sis, as well as increased infiltration of T cells. Similar
responses have been reported after thermal and mechani-
cal HIFU treatments of solid tumors (Unga and Hashida
2014; Silvestrini et al. 2017). A detailed review of abla-
tive ultrasound therapies is, however, out of the scope of
this review.
At present, the most successful form of immuno-
therapy is the administration of monoclonal antibodies
to inhibit regulatory immune checkpoints that block T-
cell action. Examples are cytotoxic T lymphocyte-asso-
ciated protein 4 (CTLA-4) and programmed cell death 1
(PD-1), which act as brakes on the immune system.
Blocking the effect of these brakes can revive and sup-
port the function of immune effector cells. Despite the
numerous successes achieved with checkpoint inhibitors,
responses have been quite heterogeneous as the success
of checkpoint inhibition therapy depends largely on the
presence of intra-tumoral effector T cells (Weber 2017).
This motivated Bulner et al. (2019) to explore the syn-
ergy of microbubble and ultrasound treatment with PD-
L1 checkpoint inhibition therapy in mice. Tumors in the
treatment group that received the combination of micro-
bubble and ultrasound treatment with checkpoint inhibi-
tion were significantly smaller than tumors in the
monotherapy groups. One mouse exhibited complete
tumor regression and remained tumor free upon rechal-
lenge, indicative of an adaptive immune response.
Overall, the number of studies that have investi-
gated the impact of microbubble and ultrasound treat-
ment on immunotherapy is limited, making this a rather
unexplored research area. It is obvious that more in-
depth research is warranted to improve our understand-
ing on how (various types of) immunotherapy might
benefit from (various types of) ultrasound treatment.BBB AND BLOODSPINAL CORD BARRIER
OPENING
The barriers of the central nervous system (CNS),
the BBB and bloodspinal cord barrier (BSCB), greatly
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riers help to regulate the specialized CNS environment
by limiting the passage of most therapeutically relevant
molecules (Pardridge 2005). Although several methods
have been proposed to circumvent the BBB and BSCB,
including chemical disruption and the development of
molecules engineered to capitalize on receptor-mediated
transport (so-called Trojan horse molecules), the use of
ultrasound in combination with microbubbles (Hynynen
et al. 2001) or droplets (Wu et al. 2018) to transiently
modulate these barriers has come to the forefront in
recent years because of the targeted nature of this
approach and its ability to facilitate delivery of a wide
range of currently available therapeutics. First demon-
strated in 2001 (Hynynen et al. 2001), ultrasound-medi-
ated BBB opening has been the topic of several hundred
original research articles in the last two decades and, in
recent years, has made headlines for groundbreaking
clinical trials targeting brain tumors and Alzheimer’s
disease as described later under Clinical Studies.
Mechanisms, bio-effects and tolerability
Ultrasound in combination with microbubbles can
produce permeability changes in the BBB via both
enhanced paracellular and transcellular transport (Shei-
kov et al. 2004, 2006). Reduction and reorganization of
tight junction proteins (Sheikov et al. 2008) and upregu-
lation of active transport protein caveolin-1 (Deng et al.
2012) have been reported. Although the exact physical
mechanisms driving these changes are not known, there
are several factors that are hypothesized to contribute to
these effects, including direct tensile stresses caused by
the expansion and contraction of the bubbles in the
lumen, as well as shear stresses at the vessel wall arising
from acoustic microstreaming. Recent studies have also
investigated the suppression of efflux transporters after
ultrasound exposure with microbubbles. A reduction in
P-glycoprotein expression (Cho et al. 2016; Aryal et al.
2017) and BBB transporter gene expression (McMahon
et al. 2018) has been observed by multiple groups. One
study found that P-glycoprotein expression was sup-
pressed for more than 48 h after treatment with ultra-
sound and microbubbles (Aryal et al. 2017). However,
the degree of inhibition of efflux transporters as a result
of ultrasound with microbubbles may be insufficient to
prevent efflux of some therapeutics (Goutal et al. 2018),
and thus this mechanism requires further study.
Many studies have documented enhanced CNS
tumor response after ultrasound and microbubble-medi-
ated delivery of drugs across the bloodtumor barrier in
rodent models. Improved survival has been observed in
both primary (Chen et al. 2010; Aryal et al. 2013) and
metastatic (Park et al. 2012; Alkins et al. 2016) tumor
models.Beyond simply enhancing drug accumulation in the
CNS, several positive bio-effects of ultrasound and
microbubble-induced BBB opening have been reported.
In rodent models of Alzheimer’s disease, numerous posi-
tive effects have been discovered in the absence of exog-
enous therapeutics. These effects include a reduction in
amyloid-b plaque load (Jord~ao et al. 2013; Burgess et al.
2014; Leinenga and G€otz 2015; Poon et al. 2018), reduc-
tion in tau pathology (Pandit et al. 2019) and improve-
ments in spatial memory (Burgess et al. 2014; Leinenga
and G€otz 2015). Two-photon microscopy has revealed
that amyloid-b plaque size is reduced in transgenic mice
for up to 2 wk after ultrasound and microbubble treat-
ment (Poon et al. 2018). Opening of the BBB in both
transgenic and wild-type mice has also revealed
enhanced neurogenesis (Burgess et al. 2014; Scarcelli
et al. 2014; Mooney et al. 2016) in the treated tissue.
Gene delivery to the CNS using ultrasound and
microbubbles is another area that is increasingly being
investigated. Viral (Alonso et al. 2013; Wang et al.
2015b) and non-viral (Mead et al. 2016) delivery meth-
ods have been investigated. While early studies reported
the feasibility of gene delivery using reporter genes
(e.g., Thevenot et al. 2012; Alonso et al. 2013), there have
been promising results delivering therapeutic genes. In
particular, advances have been made in Parkinson’s dis-
ease models, where therapeutic genes have been tested
(Mead et al. 2017; Xhima et al. 2018) and where long-
lasting functional improvements have been reported in
response to therapy (Mead et al. 2017). It is expected that
research into this highly promising technique will expand
to a range of therapeutic applications.
Despite excellent tolerability profiles in non-
human primate studies investigating repeat opening of
the BBB (McDannold et al. 2012; Downs et al. 2015),
there has been recent controversy because of reports of
a sterile inflammatory response observed in rats
(Kovacs et al. 2017a, 2017b; Silburt et al. 2017). The
inflammatory response is proportional to the magnitude
of BBB opening and is therefore strongly influenced by
experimental conditions such as microbubble dose and
acoustic settings. However, McMahon and Hynynen
(2017) reported that when clinical microbubble doses
are used, and treatment exposures are actively con-
trolled to avoid overtreating, the inflammatory response
is acute and mild. They note that while chronic inflam-
mation is undesirable, acute inflammation may actually
contribute to some of the positive bio-effects that have
been observed. For example, the clearance of amyloid-
b after ultrasound and microbubble treatment is thought
to be mediated in part by microglial activation (Jord~ao
et al. 2013). These findings reiterate the need for care-
fully controlled treatment exposures to select for
desired bio-effects.
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Fig. 4. Three-dimensional transcranial subharmonic microbub-
ble imaging and treatment control in vivo in rabbit brain during
bloodbrain barrier opening. Spectral information (top) indi-
cates the appearance of subharmonic activity at t = 35 s into the
treatment. Passive mapping of the subharmonic band localizes
this activity to the target region. Bar = 2.5 mm. Reprinted
(adapted), with permission, from Jones et al. (2018).
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It is generally accepted that the behavior of the
microbubbles in the ultrasound field is predictive, to an
extent, of the observed bio-effects. In the seminal study
on the association between cavitation and BBB opening,
McDannold et al. (2006) observed an increase in second
harmonic emissions in cases of successful opening, com-
pared with exposures that led to no observable changes
in permeability as measured by contrast-enhanced MRI.
Further, they noted that successful opening could be
achieved in the absence of inertial cavitation, which was
also reported by another group (Tung et al. 2010). These
general guidelines have been central to the development
of active treatment control schemes that have been
developed to date—all with the common goal of promot-
ing stable bubble oscillations, while avoiding violent
bubble collapse that can lead to tissue damage. These
methods are based either on detection of sub- or ultrahar-
monic (O’Reilly and Hynynen 2012; Tsai et al. 2016;
Bing et al. 2018), harmonic bubble emissions (Arvanitis
et al. 2012; Sun et al. 2017) or a combination thereof
(Kamimura et al. 2019). An approach based on the sub-/
ultraharmonic controller developed by O’Reilly and
Hynynen (2012) has been employed in early clinical test-
ing (Lipsman et al. 2018; Mainprize et al. 2019).
Control methods presented to date have generally
been developed using single receiver elements, which
simplifies data processing but does not allow signals to
be localized. Focused receivers are spatially selective
but can miss off-target events, while planar receivers
may generate false positives based on signals originating
outside the treatment volume. The solution to this is to
use an array of receivers and passive beamforming meth-
ods, combined with phase correction methods to com-
pensate for the skull bone (Jones et al. 2013, 2015), to
generate maps of bubble activity. In the brain this has
been achieved with linear arrays (Arvanitis et al. 2013;
Yang et al. 2019c), which suffer from poor axial resolu-
tion when using passive imaging methods, as well as
large-scale sparse hemispherical or large aperture
receiver arrays (O’Reilly et al. 2014; Deng et al. 2016;
Crake et al. 2018; Jones et al. 2018; Liu et al. 2018a)
that optimize spatial resolution for a given frequency.
Recently, this has extended beyond just imaging the bub-
ble activity to incorporate real-time, active feedback
control based on both the spectral and spatial informa-
tion obtained from the bubble maps (Jones et al. 2018)
(Fig. 4). Robust control methods building on these works
will be essential for widespread adoption of this technol-
ogy to ensure tolerable and consistent treatments.
BSCB opening
Despite the similarities between the BBB and
BSCB, and the great potential benefit for patients, therehas been limited work investigating translation of this
technology to the spinal cord. Opening of the BSCB in
rats was first reported by Wachsmuth et al. (2009), and
was followed by studies from Weber-Adrien et al.
(2015), Payne et al. (2017) and O’Reilly et al. (2018) in
rats (Fig. 5) and from Montero et al. (2019) in rabbits,
the latter performed through a laminectomy window. In
2018, O’Reilly et al. (2018) presented the first evidence
of a therapeutic benefit in a disease model, showing
improved tumor control in a rat model of leptomeningeal
metastases.
Although promising, significant work remains to be
done to advance BSCB opening to clinical studies. A
more thorough characterization of the bio-effects in the
spinal cord and how, if at all, they differ from those in
the brain is necessary to ensure safe translation. Addi-
tionally, methods and devices capable of delivering con-
trolled therapy to the spinal cord at clinical scale are
needed. While laminectomy and implantation of an
ultrasound device (Montero et al. 2019) might be an
appropriate approach for some focal indications, treating
multifocal or diffuse disease will require the ultrasound
Fig. 5. T1-Weighted sagittal magnetic resonance images reveal-
ing leptomeningeal tumors in rat spinal cord (gray arrowhead)
before ultrasound and microbubble treatment (left column), and
the enhancement of the cord indicating bloodspinal cord bar-
rier opening (white arrows) after ultrasound and microbubble
treatment (right column). Reprinted (adapted) with permission
from O’Reilly et al. (2018).
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nal canal. Fletcher and O’Reilly (2018) have described a
method to suppress standing waves in the human verte-
bral canal. Combined with devices suited to the spinal
geometry, such as that presented by Xu and O’Reilly,
(2020), these methods will help to advance clinical trans-
lation.
Clinical studies
The feasibility of enhancing BBB permeability in
and around brain tumors using ultrasound and microbub-
bles has now been tested in two clinical trials. In the
study conducted at Assistance Publique-Ho^pitaux de
Paris in Paris, France, an unfocused 1-MHz ultrasound
transducer (SonoCloud) was surgically placed over the
tumor resection area and permanently fixed into the hole
in the skull bone. The skin was placed over the trans-
ducer, and after healing, treatments were conducted by
inserting a needle probe through the skin to provide the
driving signal to the transducer. Monthly treatments
were then conducted while infusing a chemotherapeutic
agent into the bloodstream (carboplatin). The sonication
was executed during infusion of SonoVue microbubbles.
A constant pulsed sonication was applied during each
treatment, followed by a contrast-enhanced MRI to esti-
mate BBB permeability. The power was escalated for
each monthly treatment until enhancement was detected
on MRI. This study reported the feasibility and tolerabil-
ity (Carpentier et al. 2016), and a follow-up study may
indicate increase in survival (Idbaih et al. 2019).
The second brain tumor study was conducted at
Sunnybrook Health Sciences Centre in Toronto, Canada,
which used the InSightec Exablate 220 kHz device and
through-skull MRI-guided sonications of brain tumors
before the surgical resection. It also described thefeasibility of inducing highly localized BBB permeabil-
ity enhancement and tolerability, and reported that che-
motherapeutic concentration in the sonicated peritumor
tissue was higher than in the unsonicated tissue (Main-
prize et al. 2019).
Another study conducted in Alzheimer’s disease
patients with the Exablate device reported tolerable BBB
permeability enhancement and that the treatment could
be repeated 1 mo later without any imaging or behavior
indications of adverse events (Lipsman et al. 2018). A
third study with the same device investigated the feasi-
bility of using functional MRI to target motor cortex in
amyotrophic lateral sclerosis patients, again finding pre-
cisely targeted BBB permeability enhancement without
adverse effects in this delicate structure (Abrahao et al.
2019). All of these studies were conducted using Defi-
nity microbubbles. These studies have led to the current
ongoing brain tumor trial with six monthly treatments of
the brain tissue surrounding the resection cavity during
the maintenance phase of the treatment with temozolo-
mide. This study sponsored by InSightec is being con-
ducted in multiple institutions. Similarly, a phase II trial
in Alzheimer’s disease sonicating the hippocampus with
the goal of investigating the tolerability and potential
benefits from repeated (three treatments with 2-wk inter-
val) BBB permeability enhancement alone is ongoing.
This study is also being conducted in several institutions
that have the device.SONOTHROMBOLYSIS
Occlusion of blood flow through diseased vascula-
ture is caused by thrombi, blood clots that form in the
body. Because of limitations in thrombolytic efficacy and
speed, sonothrombolysis, ultrasound which accelerates
thrombus breakdown alone, or in combination with
thrombolytic drugs and/or cavitation nuclei, has been
under extensive investigation in the last two decades
(Bader et al. 2016). Sonothrombolysis promotes thrombus
dissolution for the treatment of stroke (Alexandrov et al.
2004a, 2004b; Molina et al. 2006; Chen et al. 2019), myo-
cardial infarction (Mathias et al. 2016, 2019; Slikkerveer
et al. 2019), acute peripheral arterial occlusion (Ebben
et al. 2017), deep vein thrombosis (DVT) (Shi et al. 2018)
and pulmonary embolism (Dumantepe et al. 2014; Engel-
berger and Kucher 2014; Lee et al. 2017).Mechanisms, agents and approaches
Ultrasound improves recombinant tissue plasmino-
gen activator (rt-PA) diffusion into thrombi and aug-
ments lysis primarily via acoustic radiation force and
streaming (Datta et al. 2006; Prokop et al. 2007; Petit
et al. 2015). Additionally, ultrasound increases rt-PA
and plasminogen penetration into the thrombus surface
Fig. 6. Simulated acoustic pressure and temperature in a repre-
sentative subject exposed to pulsed 220 kHz ultrasound with a
33.3% duty cycle. The absolute peak-to-peak pressure maxi-
mum for the simulations is displayed in gray scale. Tempera-
ture is displayed using a heat map with a minimum color
priority write threshold of 1˚C. Computed tomography features
such as bone (cyan), skin and internal epithelium (beige) and
clot (green) are plotted using contour lines. The transducer is
outlined in magenta. Constructive interference is prominent in
the soft tissue between the temporal bone and the transducer.
Some constructive interference is also present in the brain tis-
sue close to the contralateral temporal bone; however, the pres-
sure in this region did not exceed the pressure in the M1
section of the middle cerebral artery. Temperature rise was
prominent in the ipsilateral bone along the transducer axis. The
computational model is described in Kleven et al. (2019).
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ultrasonic bubble activity, or acoustic cavitation, which
induces microstreaming (Elder 1958; Datta et al. 2006;
Sutton et al. 2013). Two types of cavitation are corre-
lated with enhanced thrombolysis: stable cavitation, with
highly non-linear bubble motion resulting in acoustic
emissions at the subharmonic and ultraharmonics of the
fundamental frequency (Flynn 1964; Phelps and
Leighton 1997; Bader and Holland 2013), and inertial
cavitation, with substantial radial bubble growth and
rapid collapse generating broadband acoustic emissions
(Carstensen and Flynn 1982; Flynn 1982).
Specialized contrast agents and tailored ultrasound
schemes have been investigated with the aim of optimiz-
ing sonothrombolysis. Petit et al. (2015) observed a
greater degree of rt-PA lysis with BR38 microbubbles
exposed to 1 MHz pulsed ultrasound at an amplitude
causing inertial cavitation (1.3 MPa peak rarefactional
pressure) than at a lower amplitude causing stable cavita-
tion (0.35 MPa peak rarefactional pressure). Goyal et al.
(2017) also measured a higher degree of thrombolysis
with 1 MHz pulsed ultrasound at 1.0 MPa peak rarefac-
tional pressure with inertial cavitation than at 0.23 MPa
peak rarefactional pressure with stable cavitation in an in
vitro model of microvascular obstruction using perfluor-
obutane-filled, lipid-shelled microbubbles (Weller et al.
2002) as a nucleation agent. However, Kleven et al.
(2019) observed more than 60% fractional clot width
loss for highly retracted human whole blood clots
exposed to rt-PA, Definity and 220 kHz pulsed or contin-
uous wave (CW) ultrasound at an acoustic output with
sustained stable cavitation throughout the insonification
periods (0.22 MPa peak rarefactional pressure) (Fig. 6).
Echogenic liposomes loaded with rt-PA enhanced
lysis compared with rt-PA alone at concentrations of
1.58 and 3.15 mg/mL (Shekhar et al. 2017), suggesting
that encapsulation of rt-PA could reduce the rt-PA dose
by a factor of 2 with equivalent lytic activity. Subse-
quently it has been found that these liposomes protect rt-
PA against degradation by plasminogen activator inhibi-
tor 1, while achieving equivalent thrombolytic efficacy
relative to rt-PA, Definity and intermittent 220 kHz CW
ultrasound (Shekhar et al. 2019). Promising agents,
including a nanoscale (<100 nm) contrast agent (Bru¨ss-
ler et al. 2018) and magnetically targeted microbubbles
(De Saint Victor et al. 2019), have also exhibited
enhanced rt-PA thrombolysis in vitro. All of these inves-
tigators noted that in the absence of rt-PA, the combina-
tion of ultrasound and microbubbles did not degrade the
fibrin network.
Several minimally invasive techniques have also
been explored, with or without the inclusion of rt-PA or
exogenous cavitation nuclei. In the clinical management
of stroke, rapid treatments are needed because of theneurologist’s adage “time is brain.” Thus, treatment
options that promote fast clot removal, reduce edema
and intracerebral bleeding and improve patient outcomes
are of immense value. Magnetic resonance image-guided
HIFU has been investigated for the treatment of both
ischemic (Burgess et al. 2012) and hemorrhagic (Mon-
teith et al. 2013) stroke, and Zafar et al. (2019) have pro-
vided an excellent review of the literature for this
approach. Histotripsy, a form of HIFU that relies on the
mechanical action of microbubble clouds to ablate
thrombi with and without rt-PA (Maxwell et al. 2009;
Bader et al. 2015, 2019; Zhang et al. 2016b) is under
development to treat deep vein thrombosis. Additionally,
ultrasound-accelerated catheter-directed thrombolysis
using the EKOS system (EKOS/BTG, Bothell, WA,
USA) combines 2 MHz low-intensity pulsed ultrasound
and rt-PA without cavitation nuclei to improve lytic effi-
ciency to treat DVT (Shi et al. 2018) and pulmonary
embolism (Garcia 2015).
Cavitation monitoring
Acoustic cavitation has been reported to mediate
direct fibrinolysis (Weiss et al. 2013) and accelerated rt-
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Prokop et al. 2007; Hitchcock et al. 2011). Passive and
active cavitation detection techniques have been devel-
oped to monitor acoustic cavitation (Roy et al. 1990;
Madanshetty et al. 1991; Bader et al. 2015). Passive cav-
itation imaging, or passive acoustic mapping, employs a
transducer array that listens passively (i.e., no transmit)
to emissions from acoustically activated microbubbles
(Salgaonkar et al. 2009; Gy€ongy and Coussios 2010;
Haworth et al. 2017). Vignon et al. (2013) developed a
prototype array enabling spectral analysis of bubble
activity for sonothrombolysis applications. Superhar-
monic Doppler effects have also been utilized to monitor
bubble activity from 500 kHz pulsed therapeutic ultra-
sound (Pouliopoulos and Choi 2016). Both a linear array
(Arvanitis and McDannold 2013a, 2013b; Arvanitis
et al. 2013) and a sparse hemispherical array (Acconcia
et al. 2017) have been integrated into a clinical magnetic
resonance image-guided HIFU system to assess micro-
bubble dynamics during sonothrombolysis in the brain.Pre-clinical studies
Information gathered from animal studies can help
inform human clinical trials, despite a strong species
dependence of clot rt-PA lytic susceptibility (Gabriel
et al. 1992; Flight et al. 2006; Huang et al. 2017). A com-
prehensive systematic evaluation of 16 in vivo pre-clini-
cal sonothrombolysis studies was carried out by Auboire
et al. (2018) summarizing treatment efficacy and tolera-
bility outcomes in models of ischemic stroke. Since that
review was published, the efficacy of sonothrombolysis
using nitrogen microbubbles stabilized with a non-cross-
linked shell delivered intra-arterially through a catheter
and rt-PA delivered intravenously has been explored in a
rat model of ischemic stroke (Dixon et al. 2019).Clinical studies
There exists a rich literature on clinical trials
exploring the tolerability and efficacy of sonothromboly-
sis. Two recent meta-analyses of seven randomly
assigned controlled trials (Chen et al. 2019; Zafar et al.
2019) attempt to determine whether the administration
of rt-PA and ultrasound improves outcomes in acute
ischemic stroke. Both analyses conclude that sonothrom-
bolysis significantly enhances complete or partial recan-
alization, with improved neurologic function (assessed
via the National Institutes of Health Stroke Scale). An
ongoing clinical trial (Aureva Transcranial Ultrasound
Device With tPA in Patients With Acute Ischemic Stroke
(TRUST), NCT03519737) will determine whether large
vessel occlusions can be re-canalized with sonothrom-
bolysis (Cerevast Medical, Inc., Bothell, WA, USA) and
rt-PA, tenecteplase or alteplase (Campbell et al. 2018),while patients are transferred to a stroke center for
mechanical thrombectomy (Gauberti 2019).
Several clinical trials have indicated that high-MI
pulsed diagnostic ultrasound exposure of Definity before
and after percutaneous coronary intervention for ST ele-
vation myocardial infarction can prevent microvascular
obstruction and improve functional outcomes (Mathias
et al. 2016, 2019; Slikkerveer et al. 2019). A systematic
review of 16 catheter-directed sonothrombolysis clinical
trials composed mostly of retrospective case series using
the EKOS system without microbubble infusions deter-
mined that this treatment modality is tolerable and prom-
ising for the treatment of DVT (Shi et al. 2018).
However, a large-sample randomly assigned prospective
clinical trial is needed to improve the clinical evidence
for use as a front-line therapy for DVT. In retrospective
studies in patients with pulmonary embolism, Lee et al.
(2017) conclude that catheter-directed sonothrombolysis
is tolerable and decreases right-sided heart strain, but
Schissler et al. (2018) conclude that this therapy is not
associated with a reduction in mortality or increased res-
olution of right ventricular dysfunction. And finally, an
ongoing trial in a small cohort of 20 patients with acute
peripheral arterial occlusions (Ebben et al. 2017) will
determine whether Luminity (marketed in the United
States as Definity) and 1.8 MHz transdermal diagnostic
ultrasound with intermittent high MI (1.08) and low
MI (0.11) for visualization of the microbubbles and
flow will improve recanalization. In summary, sono-
thrombolysis has been found to have clinical benefit in
the treatment of acute and chronic thrombotic disease.
Ultrasound-assisted thrombolysis has a potential role as
an emerging viable and therapeutic option for future
management of stroke and cardiovascular disease.CARDIOVASCULAR DRUG DELIVERY AND
THERAPY
In cardiovascular drug delivery, cavitation nuclei are
co-administered or loaded with different therapeutics for the
treatment of various diseases. For atherosclerosis treatment
in an ApoE-deficient mouse model, intercellular adhesion
molecule-1-targeted microbubbles carrying the angiogene-
sis inhibitor Endostar were used (Yuan et al. 2018). Upon
intermittent insonification over the abdominal and thoracic
cavity with 1 MHz ultrasound (2 W/cm2 intensity, 50%
duty cycle) for 30 s with two repeats and another treatment
48 h later, plaque area and intraplaque neovascularization
were significantly reduced 2 wk after treatment. Percutane-
ous coronary intervention is often used to restore blood flow
in atherosclerotic arteries. The treatment of coronary micro-
embolization, a complication of percutaneous coronary
intervention, was demonstrated in pigs treated with ultra-
sound (1 MHz, 2.0 W/cm2 intensity, 10 s on and 10 s off,
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d before coronary microembolization (Su et al. 2015). This
resulted in an improved cardiac dysfunction. Although not a
therapeutic study, Liu et al. (2015) did find that plasmid
transfection to the myocardium was significantly larger
when the microbubbles were administered into the coronary
artery compared with intravenously via the ear vein in pigs
even though the intracoronary microbubble dose was half
of the intravenous dose (1 MHz ultrasound, 2 W/cm2, 50%
duty cycle, 20-min duration). Percutaneous coronary inter-
vention can also result in neointimal formation, which indu-
ces restenosis. Sirolimus-loaded microbubbles were found
to reduce neointimal formation in coronary arteries by 50%
in pigs (see Fig. 7), 28 d after angioplasty in combination
with a mechanically rotating intravascular ultrasound cathe-
ter (5 MHz, 500 cycles, 50% duty cycle, 0.6-MPa peak neg-
ative pressure) (Kilroy et al. 2015). Another research group
reported that paclitaxel-loaded microbubbles and
ultrasound (1 MHz, 1.5 MPa for 10 s) can also signif-
icantly inhibit neointimal formation in the iliac artery
in rabbits 1 wk after percutaneous coronary interven-
tion (Zhu et al. 2016).
In diabetic cardiomyopathy, microbubble-mediated
delivery of fibroblast growth factor has shown therapeu-
tic effects. Zhao et al. (2016) could prevent diabetic car-
diomyopathy in rats by treating the heart with ultrasound
(14 MHz, 7.1 MPa for 10 s, three repeats with off inter-
val of 1 s) and microbubbles co-administered with acidic
fibroblast growth factor nanoparticles twice weekly for
12 consecutive wk. In already established diabetic car-
diomyopathy in rats, the same investigators co-adminis-
tered basic fibroblast growth factor-containing
nanoparticles with microbubbles with the same ultra-
sound treatment, albeit that it was given three times with
1 d in between treatments. At 4 wk after treatment, this
resulted in restored cardiac function as a result of struc-
tural remodeling of the cardiac tissue (Zhao et al. 2014).
Microbubbles loaded with acidic fibroblast growth factor
in combination with ultrasound (14 MHz, 7.1 MPa for
10 s, three repeats with off interval of 1 s) also resulted
in significantly improved cardiac function in a rat model
of diabetic cardiomyopathy. Treatment was performed
twice weekly for 12 consecutive wk (Zhang et al.
2016a). For doxorubicin-induced cardiomyopathy,
repeated co-administration of microbubbles and nano-
particles containing acidic fibroblast growth factor in
combination with ultrasound (14 MHz, 7.1 MPa for 10 s,
three repeats with off interval of 1 s) applied at the heart
successfully prevented doxorubicin-induced cardiomy-
opathy in rats (Tian et al. 2017). Once doxorubicin-
induced cardiomyopathy had occurred, microbubble-
mediated reversal of cardiomyopathy was shown by the
delivery of surviving plasmid to cardiomyocytes and
endothelial cells (Lee et al. 2014) or glucagon-likepeptide-1 to cardiomyocytes, endothelial cells, vascular
muscle cells and mesenchymal cells (Chen et al. 2015)
in rats. The ultrasound settings were 5 MHz (120 V
power, pulsing interval of 10 cardiac cycles at end-sys-
tole) for a 5 min treatment (Lee et al. 2014) or not speci-
fied (Chen et al. 2015). The microbubble-mediated gene
therapy study by Chen et al. (2016) indicated that
ANGPTL8 gene therapy does not need to be done in the
heart to reverse doxorubicin-induced cardiomyopathy in
rats as their microbubble and ultrasound (1.3 MHz, 1.4
MPa peak negative pressure, four bursts triggered to
every fourth end-systole using a delay of 4570 ms of
the peak of the R wave) therapy was done in the liver
(90 s treatment). This resulted in overexpression of
ANGPTL8 in liver cells and blood, which stimulated
cardiac progenitor cells in the epicardium.
A few dozen articles have been published on treat-
ing myocardial infarction with microbubble and ultra-
sound-mediated gene delivery in vivo, in mouse, rat,
rabbit and dog models. These are reviewed by Qian et al.
(2018). Amongst these are a few targeted microbubble
studies which all indicate that the targeted microbubbles
induced higher degrees of gene transfection, increased
myocardial vascular density and improved cardiac func-
tion in comparison to non-targeted microbubbles. This
improvement occurred independent of the type of ligand
on the microbubble, the gene that was transfected or the
animal model: matrix metalloproteinase 2 target with
Timp3 gene in rats (Yan et al. 2014), intracellular adhe-
sion molecule-1 target with Ang-1 gene in rabbits (Deng
et al. 2015), P-selectin target with hVEGF165 gene in
rats (Shentu et al. 2018). Ultrasound settings for these
studies were similar at 1.6 MHz (1.6 MPa peak negative
pressure, pulsing interval of 4 cardiac cycles) for 20 min
during infusion of the plasmid-loaded microbubbles
(both Yan et al. [2014] and Shentu et al. [2018]) or
1.7 MHz (1.7 MPa peak negative pressure, pulsing inter-
val every 48 cardiac cycles) for 5 min after bolus injec-
tion of the plasmid-loaded microbubbles (Deng et al.
2015).
Other gene therapy studies for vascular disease
include stimulating angiogenesis for the treatment of
chronic hindlimb ischemia in rats using miR-126-3p-
loaded microbubbles and ultrasound (1.3 MHz, 2.1 MPa
peak negative acoustic pressure, pulsing interval 5 s).
The treatment lasted 20 min during which microbubbles
were infused for 10 min and resulted in improved perfu-
sion, vessel density, arteriolar formation and neovessel
maturation (Cao et al. 2015). Recently, successful gene
therapy was reported in baboons in which vascular endo-
thelial growth factor (VEGF)-plasmid loaded microbub-
bles were infused and ultrasound (26 MHz, MI 1.9,
repeated 5 s burst pulses with three bursts per min) was
applied for 10 min on days 25, 35, 45 and 55 of
Fig. 7. Histologic sections of a coronary artery of a pig 28 d
after angioplasty. Pigs were treated with sirolimus-loaded
microbubbles only (a) or sirolimus-loaded microbubbles and
ultrasound (b) using a mechanically rotating intravascular
ultrasound catheter (5 MHz, 500 cycles, 50% duty cycle, 0.6
MPa peak negative pressure). Treatment with ultrasound and
sirolimus-loaded microbubbles reduced neointimal formation
by 50%. In both sections, the intima (I) and media (M) are out-
lined. Bar = 500 mm. Reprinted with permission from Springer
Nature: Springer, Annals of Biomedical Engineering, Reducing
Neointima Formation in a Swine Model with IVUS and Siroli-
mus Microbubbles, Kilroy JP, Dhanaliwala AH, Klibanov AL,
Bowles DK, Wamhoff BR, Hossack JA, COPYRIGHT, from
Kilroy JP et al. (2015).
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basal plate (Babischkin et al. 2019). This was a mecha-
nistic study elucidating the role of VEGF in uterine
artery remodeling.
The gas core of the cavitation nuclei can also be the
therapeutic. Sutton et al. (2014) have found that ultra-
sound-mediated (1 MHz, 0.34 MPa acoustic pressure, 30
cycle pulse, 50 s treatment) nitric oxide gas delivery
from echogenic liposomes to ex vivo-perfused porcine
carotid arteries induces potent vasorelaxation. The vaso-
dilative effect of nitric oxide-loaded echogenic lipo-
somes upon insonification (5.7 MHz, 0.36 MPa peak
negative pressure, 30 s treatment) was also shown in ex
vivo perfused rabbit carotid arteries with arterial wall
penetration of nitric oxide confirmed by fluorescence
microscopy (Kim et al. 2014). In addition to this, vasodi-
lative effects were reported in carotid arteries in vivo in
rats with vasospasms after subarachnoid hemorrhage
using 1 MHz ultrasound with 0.3 MPa peak-to-peak
pressure, 50% duty cycle for a duration of 40 min with
constant infusion of the echogenic liposomes. This
resulted in improved neurologic function (limb place-
ment, beam and grid walking) (Kim et al. 2014). Ultra-
sound activation of the antioxidant hydrogen gas
encapsulated in microbubbles was reported to prevent
myocardial ischemiareperfusion injury in rats when
administered before reperfusion (He et al. 2017). Therewas a dose-dependent effect as 2£ 1010 microbubbles
resulted in a more significant reduction in infarct size
(70%) than 4£ 109 microbubbles (39%) compared with
vehicle-treated rats. Furthermore, treatment with the
high-dose hydrogen microbubbles prevented changes in
left ventricular end-diastolic and left ventricular end-sys-
tolic dimensions, as well as minimal reductions in ejec-
tion fraction and fractional shortening. Histologic and
ELISA analyses revealed a reduced degree of myocar-
dial necrosis, apoptosis, hemorrhaging, inflammation
and oxidant damage. At the same time that cardiovascu-
lar drug delivery and therapy using microbubbles and
ultrasound is moving forward to large animal and clini-
cal studies, sophisticated in vitro models are being used
and/or developed for mechanistic studies, such as flow
chambers (mSlides, Ibidi) (Shamout et al. 2015) and per-
fused 3-D microvascular networks (Juang et al. 2019), in
which human umbilical vein endothelial cells are grown.Clinical study
Microbubbles and ultrasound were clinically inves-
tigated to augment muscle blood flow in 12 patients with
stable sickle cell disease in the absence of a drug at the
Oregon Health & Science University, Portland, Oregon,
USA (Belcik et al. 2017). Perfusion increased »2-fold in
the forearm flexor muscles upon Definity infusion and
insonification at 1.3 MHz (MI 1.3). Ultrasound was
applied three times for 3 min with »5 min intervals. The
change in perfusion was determined from contrast-
enhanced ultrasound imaging and extended well beyond
the region where ultrasound was applied. This study
indicated that the therapeutic ultrasound settings directly
translate from mouse to human for superficial muscles,
as the same investigators found augmented blood flow in
ischemic and non-ischemic hindlimb muscles in mice in
the same study and an earlier publication (Belcik et al.
2015). However, for the pre-clinical studies, custom-
made microbubbles were used instead of Definity.SONOBACTERICIDE
Sonobactericide has been defined as the use of ultra-
sound in the presence of cavitation nuclei for the enhance-
ment of bactericidal action (Lattwein et al. 2018). This
topic has recently gained attention, with 17 papers being
published in the last 5 y. Research on ultrasound-mediated
enhancement of antimicrobials has focused on several
sources of infections including general medical devices
(Ronan et al. 2016; Dong et al. 2017, 2018; Hu et al.
2018; Fu et al. 2019), acne (Liao et al. 2017), chronic bac-
terial prostatitis (Yi et al. 2016), infective endocarditis
(Lattwein et al. 2018), pneumonia (Sugiyama et al. 2018),
prosthetic joint infections (Li et al. 2015; Lin et al. 2015;
Guo et al. 2017a; Zhou et al. 2018) and urinary tract
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specific disease aim in two studies (Zhu et al. 2014; Goh
et al. 2015). One group targeted membrane biofouling for
water and wastewater industries (Agarwal et al. 2014).
Direct bacterial killing, biofilm degradation and dispersal
and increased or synergistic therapeutic effectiveness of
antimicrobials have been reported as the therapeutic
effects of sonobactericide. These studies show that sono-
bactericide can be applied to treat Gram+ or Gram bacte-
ria, when they are planktonic, associated with a surface and
embedded in biofilm, or intracellular. The majority of these
studies were carried out in vitro. However, seven were per-
formed in vivo in either mice (Li et al. 2015; Liao et al.
2017; Sugiyama et al. 2018; Zhou et al. 2018), rats (Yi et al.
2016) or rabbits (Lin et al. 2015; Dong et al. 2018). Sono-
bactericide was mostly performed with co-administration of
antimicrobials. Investigators also employed an antimicrobial
encapsulated in liposomes that were conjugated to the
microbubbles (Horsley et al. 2019), or the antimicrobial
lysozyme was a microbubble coating (Liao et al. 2017) or
did not use antimicrobials altogether (Agarwal et al. 2014;
Goh et al. 2015; Yi et al. 2016). An extensive review of
sonobactericide has been published recently by Lattwein
et al. (2020). Although sonobactericide is an emerging strat-
egy to treat bacterial infections with intriguing potential, the
mechanism and safety of the treatment should be explored,
particularly with respect to biofilm degradation and dis-
persal. Future studies should also focus on maximizing the
efficacy of sonobactericide in situ.Fig. 8. Different time scales of the therapeutic effects of ultras
lar calcium; ROS = reactive oxygen species; ATP = adenosi
(adapted) with permission fromFUTURE PERSPECTIVES AND CONCLUSIONS
Therapeutic ultrasound technology is experiencing
a paradigm shift in terms of both technical developments
and clinical applications. In addition to its inherent
advantages for imaging (e.g., real-time nature, portabil-
ity and low cost), ultrasound in combination with cavita-
tion nuclei is under exploration as a drug delivery
modality. The results from several pre-clinical studies
have already illustrated the potential of ultrasound-
responsive cavitation nuclei to deliver multiple types of
drugs (including model drugs, anticancer drugs, thera-
peutic antibodies, genes and nanoparticles) efficiently in
various tumor models, including both ectopic and ortho-
topic models, for immunotherapy, brain disease, dissolu-
tion of clots and treatment of cardiovascular disease and
bacterial infections.
Based on these encouraging pre-clinical data,
several clinical trials have been initiated and others
are planned. However, whilst animal studies provide
proof of concept and impetus for clinical studies,
careful attention must be given to their relevance in
human disease, in particular, the applicability of ther-
apeutic protocols and appropriate ultrasound settings.
Otherwise we risk underestimating the therapeutic
effects and potential deleterious side effects. The elu-
cidation of all of the interactions between cavitation
nuclei, cells and drugs will help to address this need.
The biggest challenges lie in the large differences in
time scales between the cavitation initiation, drugound and cavitation nuclei treatment. [Ca2+]i = intracellu-
ne triphosphate; EV = extracellular vesicles. Reprinted
Lattwein et al. (2020).
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A multidisciplinary approach is needed to tackle these
challenges integrating expertise in physics, biophys-
ics, biology, chemistry and pharmacology.
Custom-made microbubbles which serve as cavi-
tation nuclei are often used for ultrasound-mediated
drug delivery studies. An advantage is full control
over the payload, as well as the disease target. At the
same time, full acoustical characterization and steril-
ity of the microbubbles must be considered during
translation to human studies, which often requires
approval from the U.S. Food and Drug Administra-
tion (FDA) or other similar federal agencies in
Europe and Asia. As an example, for gene therapy,
will each different type of genetic material loaded
onto microbubbles need such approval, or will a class
of cationic microbubbles be approved regardless of
the specific gene? The former path would hinder fast
clinical translation. For now, co-administration of
drugs with FDA-approved ultrasound contrast agents
is being explored in clinical trials. Apart from appli-
cations in the brain, ongoing clinical studies evaluat-
ing microbubble-mediated drug delivery are based on
standard clinical ultrasound scanners operating mostly
in Doppler mode. To promote the progress of this
emerging technology, it is very important to design
and implement specific therapeutic ultrasound pulse
sequences that might be vastly different from clinical
diagnostic imaging output. Clinical scanners can
indeed be modified to be able to generate drug deliv-
ery protocols. In a similar way that elastography
requires long ultrasound pulses to generate the push
sequences (Deffieux et al. 2009), ultrasound scanners
can be modified to be able to transmit drug delivery
ultrasound sequences with tailored and optimized
parameters (pulse duration, duty cycle and center fre-
quency).
Ultimately, ultrasound image-guided drug delivery
and the monitoring of treatment response could be feasi-
ble with the same equipment. Additionally, with recent
developments in ultrasound imaging technology, ultra-
sound-mediated therapy could be planned, applied and
monitored in a rapid sequence with high spatial and tem-
poral resolution. The use of a single imaging and therapy
device would alleviate the need for co-registration,
because the imaging equipment would also be used to
induce localized therapy ensuring a perfect co-location.
Nonetheless, a compromise between efficacy and safety
remains a major challenge for successful clinical appli-
cations of this dual methodology, which combines real-
time image guidance of therapeutic delivery.
In conclusion, ultrasound-responsive microbubbles
which serve as cavitation nuclei are being used to treat a
wide variety of diseases and show great potentialpreclinically and clinically. The elucidation of the cavi-
tation nucleicell interaction and the implementation of
drug delivery ultrasound sequences on clinical ultra-
sound scanners are expected to invigorate clinical stud-
ies.
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